HIMS Surges 49%: Will Wegovy Partnership Rally Last Longer?

Hims & Hers Health Inc. (HIMS) witnessed an explosive 49% surge in Monday’s premarket trading, erasing months of regulatory gloom. The catalyst is a blockbuster report from Bloomberg: Novo Nordisk, the maker of Wegovy, has reportedly agreed to settle its bitter legal battle and will now officially sell its FDA-approved weight-loss drugs through the Hims & Hers platform. With the "legal overhang" gone, can HIMS reclaim its 52-week high of $70, or is the 49% jump a "sell the news" event?Will this settlement pave the way for a full-scale acquisition of HIMS by a Big Pharma giant in late 2026?

+ Follow

Isleigh

03-15

HIMS Surges 49%: Is This the Start of a Digital Healthcare Supercycle?‌

$Hims & Hers Health Inc.(HIMS)$ When a stock jumps nearly 50% in premarket, investors usually assume the move is already over. But sometimes, a sudden surge is not the end of a rally. It is the start of a new narrative. That may be what we are witnessing with Hims & Hers Health (HIMS). The catalyst? A reported settlement between Novo Nordisk and HIMS, clearing the path for the Wegovy weight loss drug to be sold through HIMS platform. On the surface, this looks like a simple distribution agreement. In reality, it could represent something much bigger: the merging of Big Pharma with digital health infrastructure. Why the Market Reacted So Violently The 49% surge was not just excitement. It was the removal of a

HIMS Surges 49%: Is This the Start of a Digital Healthcare Supercycle?‌

MdNasir

03-15

$Hims & Hers Health Inc.(HIMS)$ looking good

Liang888

03-15

$Hims & Hers Health Inc.(HIMS)$ #HIMS has high potential to 2x-4x from here after being going up more than 50% for the past 5 days. Very good risk to rewards.

Pank

03-11

#Hims doubling due to drug approval

Sigmaslayer

03-10

$Hims & Hers Health Inc.(HIMS)$ indeed

Lanceljx

03-09

$Hims & Hers Health Inc.(HIMS)$ The pre-market surge in Hims & Hers Health Inc. following a reported settlement with Novo Nordisk is a significant narrative shift. For months, regulatory uncertainty around weight-loss drug distribution had weighed on sentiment. If Novo’s Wegovy is indeed sold through the Hims platform, it transforms HIMS from a telehealth subscription company into a distribution gateway for GLP-1 therapies, which is a far larger market. Can it reclaim $70? A move toward the prior high is plausible, but the 49% gap introduces short-term risks. Bullish factors Direct access to FDA-approved GLP-1 drugs boosts credibility and revenue potential. Telehealth + obesity treatment is one of the fastest-growing healthcare segme

Shernice軒嬣 2000

03-07

Muthu Boy Alert: Hims & Hers Health (HIMS) Jumps 37% After Hours — 39% Short Interest Could Spark $100 Short Squeeze 🚀

Congrats to all the $Hims & Hers Health Inc.(HIMS)$ holders — the stock just jumped 40% after hours! 🚀 Looks like Novo Nordisk (Novo Nordisk (NVO)) may have dropped the lawsuit and decided to partner with HIMS, selling Novo-branded GLP-1 receptor agonists. $NVO Novo Nordisk on Danish newspaper Børsen: "We are in ongoing dialogue with companies that can help improve patient access to regulatory

Muthu Boy Alert: Hims & Hers Health (HIMS) Jumps 37% After Hours — 39% Short Interest Could Spark $100 Short Squeeze 🚀

HRHRHRHR

03-07

$Hims & Hers Health Inc.(HIMS)$ 7 Mar - Missed this 40%+ pump. Waited for $13 but did not happened. Congrats to those who got it at $14-$15 when no one believed in the stock.. [Miser] [Miser] [Miser]

Shernice軒嬣 2000

03-07

Novo & Hims Tie the Knot Again 💍 Muthu Boy Cheers, Prata on the Side?

Divorced Last Year, Married Again This Monday? Novo & Hims’ Comeback” $Hims & Hers Health Inc.(HIMS)$ Novo and Hims look like they’re getting married again 💍 after last year’s messy divorce. Hims pops 35% in after hours. The two companies are expected to announce a new partnership as early as Monday, according to a person familiar with the matter who spoke on condition of anonymity. They were previously together, but Novo abruptly called it quits after Hims refused to stop promoting and selling copycat medications. Now it seems the former couple may be giving love another chance and Muthu boy is very happy to see the reunion 😊. I wonder… will they order my roti prata from my prata shop? 🥞✨

Novo & Hims Tie the Knot Again 💍 Muthu Boy Cheers, Prata on the Side?

Shernice軒嬣 2000

03-06

Patent Cliff Hits: India, China & Brazil Unlock Cheap Semaglutide – Hims & Hers Poised to Dominate Globally!

Big news for weight loss access! Semaglutide patents are expiring soon in countries like India, China, and Brazil (starting March 2026) – meaning super-cheap generic versions are coming! $Hims & Hers Health Inc.(HIMS)$ Here's why this could be a game-changer for Hims & Hers (and patients worldwide): Lower Costs As patents expire, raw ingredient (API) prices will crash. If manufacturing drops to ~$3/month, Hims & Hers can slash subscription prices big time – making effective weight loss meds affordable instead of $200–$1,000/month for branded versions. More people can finally access it! Global Expansion Hims & Hers is already pushing internationally (just entered Canada!). With cheap, legal generi

Patent Cliff Hits: India, China & Brazil Unlock Cheap Semaglutide – Hims & Hers Poised to Dominate Globally!

AfraSimon

03-05

Bear Case on $HIMS: Valuation Risk, GLP-1 Threat, and Slowing Growth

Pure $Hims & Hers Health Inc.(HIMS)$ delulu copium. Bearish catalysts: 1) Still trading at 32 P/E, despite the core profit driver under attack. If GLP1s go to zero, profits fall 80-120%. Overvalued. 2) Growth is not "sandbagged", its the opposite. $HIMS 2026 and 2030 guidances are aggressive and unachievable without M&A. 3) Newly acquired international segments are stinkers and unprofitable. Everyone knows that $HIMS is the sucker to sell to. Watch for international growth to suffer because of "macro and War in Iran" (Excuses). 4) Peptide approval is not the catalyst HIMS hopes for. It's the opposite, regulators are talking of banning the sale of certain peptides and stricter regulations. 5) Wearables is just delusion, HIMS can't compete w

Bear Case on $HIMS: Valuation Risk, GLP-1 Threat, and Slowing Growth

andy_88

03-05

$HIMS 20260327 15.0 PUT$

NAI500

03-04

$150 Billion Weight-Loss Drug Market Temptation: Novo Nordisk Expands Production Against the Tide

Facing Eli Lilly’s competition and short-term sales slumps, can NVO reclaim its GLP-1 dominance in the $150B market? Are you bullish on its long-term bet, or is LLY a better pick? Share your thoughts on the weight-loss drug race below! To consolidate its position in the global weight-loss drug market, Danish pharmaceutical giant $Novo-Nordisk A/S(NVO)$ is accelerating capacity expansion. According to local media reports on Monday, the company will invest €432 million (approximately $507 million) to upgrade its factory in Athlone, Ireland, to produce its blockbuster weight-loss drug Wegovy for markets outside the United States. A company spokesperson has confirmed the scale of this investment. The upgrade will significantly enhance its production ca

$150 Billion Weight-Loss Drug Market Temptation: Novo Nordisk Expands Production Against the Tide

Travis Hoium

03-03

$HIMS Eyes Multi-Billion-Dollar Peptide Boom as 19 Key Compounds Gain Traction

Peptides could be a new multi-billion-dollar market for companies like Hims & Hers $HIMS. What are these peptides, and what do they do? Here's what you need to know about all 19 peptides in question today, 14 of which may soon be legal to compound (according to RFK) 👇 1. BPC-157 Note: These infographics are made by Gemini and are for informational purposes only. 2. Thymosin Alpha-1 (Ta1) 3. Thymosin Beta-4 Fragment (TB-500) 4. AOD-9604 5. CJC-1295 6. Ipamorelin Acetate 7. Selank Acetate (TP-7) 8. Semax 9. GHK-Cu (Copper Peptide) 10. GHRP-2 11. GHRP-6 12. Epitalon 13. KPV 14. Kisspeptin-10 15. Melanotan II 16. MOTS-c 17. PEG-MGF (Pegylated Mechano Growth Factor) 18. Emideltide (DSIP - Delta Sleep-Inducing Peptide) 19. Cathelicidin LL-37 For SG users only, Welcome to open a CBA today and

$HIMS Eyes Multi-Billion-Dollar Peptide Boom as 19 Key Compounds Gain Traction

{"data":{"themeId":"e8b7f11d43e746678c9aef4fb3796f28","name":"HIMS Surges 49%: Will Wegovy Partnership Rally Last Longer?","description":"Hims & Hers Health Inc. (HIMS) witnessed an explosive 49% surge in Monday’s premarket trading, erasing months of regulatory gloom. The catalyst is a blockbuster report from Bloomberg: Novo Nordisk, the maker of Wegovy, has reportedly agreed to settle its bitter legal battle and will now officially sell its FDA-approved weight-loss drugs through the Hims & Hers platform. With the \"legal overhang\" gone, can HIMS reclaim its 52-week high of $70, or is the 49% jump a \"sell the news\" event?Will this settlement pave the way for a full-scale acquisition of HIMS by a Big Pharma giant in late 2026?","image":"https://community-static.tradeup.com/news/187a191e57cb1313b5da2207a50ecb19","type":0,"style":1,"follow":false,"createTime":1773047764314,"userCounts":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":e8b7f11d43e746678c9aef4fb3796f28}&rnconfig={\"headerBarHidden\": true}","subscribe":false,"allowSubscriptionFinancial":false,"subscriberCount":0,"allowFollow":true,"hasReward":true,"rewardScore":1000,"rewardValidDate":1773590400000,"rewardEnd":true,"symbols":["HIMS"],"tweetCounts":29,"categoryId":"7a15628ce2174325bddc6229505e0d70","options":[],"votedOptionId":"","totalUserCount":0,"followStatus":false,"themeName":"HIMS Surges 49%: Will Wegovy Partnership Rally Last Longer?","tweetAmount":29,"imageIsDefault":false,"aiDerivativeIssues":[]},"tab":"all","allList":[{"id":542956483367992,"gmtCreate":1773585553850,"gmtModify":1773652602565,"author":{"id":"4147681045299222","authorId":"4147681045299222","name":"Isleigh","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4147681045299222","idStr":"4147681045299222"},"themes":[],"title":"HIMS Surges 49%: Is This the Start of a Digital Healthcare Supercycle?‌","htmlText":"<a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a><v-v data-views=\"1\"></v-v> When a stock jumps nearly 50% in premarket, investors usually assume the move is already over. But sometimes, a sudden surge is not the end of a rally. It is the start of a new narrative. That may be what we are witnessing with Hims &amp; Hers Health (HIMS). The catalyst? A reported settlement between Novo Nordisk and HIMS, clearing the path for the Wegovy weight loss drug to be sold through HIMS platform. On the surface, this looks like a simple distribution agreement. In reality, it could represent something much bigger: the merging of Big Pharma with digital health infrastructure. Why the Market Reacted So Violently The 49% surge was not just excitement. It was the removal of a","listText":"<a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a><v-v data-views=\"1\"></v-v> When a stock jumps nearly 50% in premarket, investors usually assume the move is already over. But sometimes, a sudden surge is not the end of a rally. It is the start of a new narrative. That may be what we are witnessing with Hims &amp; Hers Health (HIMS). The catalyst? A reported settlement between Novo Nordisk and HIMS, clearing the path for the Wegovy weight loss drug to be sold through HIMS platform. On the surface, this looks like a simple distribution agreement. In reality, it could represent something much bigger: the merging of Big Pharma with digital health infrastructure. Why the Market Reacted So Violently The 49% surge was not just excitement. It was the removal of a","text":"$Hims & Hers Health Inc.(HIMS)$ When a stock jumps nearly 50% in premarket, investors usually assume the move is already over. But sometimes, a sudden surge is not the end of a rally. It is the start of a new narrative. That may be what we are witnessing with Hims & Hers Health (HIMS). The catalyst? A reported settlement between Novo Nordisk and HIMS, clearing the path for the Wegovy weight loss drug to be sold through HIMS platform. On the surface, this looks like a simple distribution agreement. In reality, it could represent something much bigger: the merging of Big Pharma with digital health infrastructure. Why the Market Reacted So Violently The 49% surge was not just excitement. It was the removal of a","images":[{"img":"https://community-static.tradeup.com/news/9dbaaea9f1e62490d55675083e4f7a53","width":"1024","height":"1536"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":4,"commentSize":2,"repostSize":1,"link":"https://ttm.financial/post/542956483367992","isVote":1,"tweetType":1,"viewCount":710,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3527667614729340","authorId":"3527667614729340","name":"chipzzy","avatar":"https://static.tigerbbs.com/cb1b514fb84e9876b2ede5b6bd40c4cb","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3527667614729340","idStr":"3527667614729340"},"content":"Impressive move! If it holds above $30, massive upside potential lah.[看涨]","text":"Impressive move! If it holds above $30, massive upside potential lah.[看涨]","html":"Impressive move! If it holds above $30, massive upside potential lah.[看涨]"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":542825922762160,"gmtCreate":1773553575007,"gmtModify":1773553578965,"author":{"id":"3571373255567067","authorId":"3571373255567067","name":"MdNasir","avatar":"https://static.tigerbbs.com/7f710cb4dfa7ce6c2ad0e54d32ba876c","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3571373255567067","idStr":"3571373255567067"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a> looking good","listText":"<a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a> looking good","text":"$Hims & Hers Health Inc.(HIMS)$ looking good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/542825922762160","isVote":1,"tweetType":1,"viewCount":137,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":542738611512536,"gmtCreate":1773532375095,"gmtModify":1773532379054,"author":{"id":"3574483723803783","authorId":"3574483723803783","name":"Liang888","avatar":"https://static.tigerbbs.com/9119b5ac937586de632c5522c9a50377","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3574483723803783","idStr":"3574483723803783"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a> #HIMS has high potential to 2x-4x from here after being going up more than 50% for the past 5 days. Very good risk to rewards.","listText":"<a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a> #HIMS has high potential to 2x-4x from here after being going up more than 50% for the past 5 days. Very good risk to rewards.","text":"$Hims & Hers Health Inc.(HIMS)$ #HIMS has high potential to 2x-4x from here after being going up more than 50% for the past 5 days. Very good risk to rewards.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/542738611512536","isVote":1,"tweetType":1,"viewCount":235,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":541490709661008,"gmtCreate":1773227590397,"gmtModify":1773234275979,"author":{"id":"4201036395308442","authorId":"4201036395308442","name":"Pank","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4201036395308442","idStr":"4201036395308442"},"themes":[],"title":"","htmlText":"#Hims doubling due to drug approval&nbsp;","listText":"#Hims doubling due to drug approval&nbsp;","text":"#Hims doubling due to drug approval","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/541490709661008","isVote":1,"tweetType":1,"viewCount":247,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":541056315569384,"gmtCreate":1773112944900,"gmtModify":1773116418644,"author":{"id":"4228822863180962","authorId":"4228822863180962","name":"Sigmaslayer","avatar":"https://community-static.tradeup.com/news/ab2daff12c162bd81a5c90ba3a86b172","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4228822863180962","idStr":"4228822863180962"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a> indeed&nbsp;","listText":"<a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a> indeed&nbsp;","text":"$Hims & Hers Health Inc.(HIMS)$ indeed","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/541056315569384","isVote":1,"tweetType":1,"viewCount":358,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":540831323477576,"gmtCreate":1773060505956,"gmtModify":1773134625461,"author":{"id":"4176423247955812","authorId":"4176423247955812","name":"Lanceljx","avatar":"https://community-static.tradeup.com/news/09909b81957df6057776741ed24e12fe","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4176423247955812","idStr":"4176423247955812"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a> The pre-market surge in Hims &amp; Hers Health Inc. following a reported settlement with Novo Nordisk is a significant narrative shift. For months, regulatory uncertainty around weight-loss drug distribution had weighed on sentiment. If Novo’s Wegovy is indeed sold through the Hims platform, it transforms HIMS from a telehealth subscription company into a distribution gateway for GLP-1 therapies, which is a far larger market. Can it reclaim $70? A move toward the prior high is plausible, but the 49% gap introduces short-term risks. Bullish factors Direct access to FDA-approved GLP-1 drugs boosts credibility and revenue potential. Telehealth + obesity treatment is one of the fastest-growing healthcare segme","listText":"<a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a> The pre-market surge in Hims &amp; Hers Health Inc. following a reported settlement with Novo Nordisk is a significant narrative shift. For months, regulatory uncertainty around weight-loss drug distribution had weighed on sentiment. If Novo’s Wegovy is indeed sold through the Hims platform, it transforms HIMS from a telehealth subscription company into a distribution gateway for GLP-1 therapies, which is a far larger market. Can it reclaim $70? A move toward the prior high is plausible, but the 49% gap introduces short-term risks. Bullish factors Direct access to FDA-approved GLP-1 drugs boosts credibility and revenue potential. Telehealth + obesity treatment is one of the fastest-growing healthcare segme","text":"$Hims & Hers Health Inc.(HIMS)$ The pre-market surge in Hims & Hers Health Inc. following a reported settlement with Novo Nordisk is a significant narrative shift. For months, regulatory uncertainty around weight-loss drug distribution had weighed on sentiment. If Novo’s Wegovy is indeed sold through the Hims platform, it transforms HIMS from a telehealth subscription company into a distribution gateway for GLP-1 therapies, which is a far larger market. Can it reclaim $70? A move toward the prior high is plausible, but the 49% gap introduces short-term risks. Bullish factors Direct access to FDA-approved GLP-1 drugs boosts credibility and revenue potential. Telehealth + obesity treatment is one of the fastest-growing healthcare segme","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":21,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/540831323477576","isVote":1,"tweetType":1,"viewCount":1773,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":540013639611736,"gmtCreate":1772860976843,"gmtModify":1773047808822,"author":{"id":"3560184106659134","authorId":"3560184106659134","name":"Shernice軒嬣 2000","avatar":"https://community-static.tradeup.com/news/6eb28f05fb053c58e617cac286725dc1","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3560184106659134","idStr":"3560184106659134"},"themes":[],"title":"Muthu Boy Alert: Hims & Hers Health (HIMS) Jumps 37% After Hours — 39% Short Interest Could Spark $100 Short Squeeze 🚀","htmlText":"Congrats to all the <a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;&nbsp;holders — the stock just jumped 40% after hours! 🚀 Looks like <a href=\"https://ttm.financial/J/showDialog/word_explain?id=1993157573763031040&amp;word=Novo Nordisk\">Novo Nordisk</a> (<a href=\"https://ttm.financial/J/showDialog/word_explain?id=1993157573763031040&amp;word=Novo Nordisk\">Novo Nordisk</a> (NVO)) may have dropped the lawsuit and decided to partner with HIMS, selling Novo-branded <a href=\"https://ttm.financial/J/showDialog/word_explain?id=1993149254180691968&amp;word=GLP-1\">GLP-1</a> receptor agonists. $NVO Novo Nordisk on Danish newspaper Børsen: \"We are in ongoing dialogue with companies that can help improve patient access to regulatory","listText":"Congrats to all the <a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;&nbsp;holders — the stock just jumped 40% after hours! 🚀 Looks like <a href=\"https://ttm.financial/J/showDialog/word_explain?id=1993157573763031040&amp;word=Novo Nordisk\">Novo Nordisk</a> (<a href=\"https://ttm.financial/J/showDialog/word_explain?id=1993157573763031040&amp;word=Novo Nordisk\">Novo Nordisk</a> (NVO)) may have dropped the lawsuit and decided to partner with HIMS, selling Novo-branded <a href=\"https://ttm.financial/J/showDialog/word_explain?id=1993149254180691968&amp;word=GLP-1\">GLP-1</a> receptor agonists. $NVO Novo Nordisk on Danish newspaper Børsen: \"We are in ongoing dialogue with companies that can help improve patient access to regulatory","text":"Congrats to all the $Hims & Hers Health Inc.(HIMS)$ holders — the stock just jumped 40% after hours! 🚀 Looks like Novo Nordisk (Novo Nordisk (NVO)) may have dropped the lawsuit and decided to partner with HIMS, selling Novo-branded GLP-1 receptor agonists. $NVO Novo Nordisk on Danish newspaper Børsen: \"We are in ongoing dialogue with companies that can help improve patient access to regulatory","images":[{"img":"https://community-static.tradeup.com/news/d58a2174eafc0bfad283816d4fd66678","width":"1079","height":"1761"},{"img":"https://community-static.tradeup.com/news/034f2f18706ab3991c1147b39d5040b9","width":"1290","height":"1843"},{"img":"https://community-static.tradeup.com/news/cb21bdaf4165384012735cfaef880955","width":"1080","height":"1700"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":5,"commentSize":10,"repostSize":3,"link":"https://ttm.financial/post/540013639611736","isVote":1,"tweetType":1,"viewCount":2476,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3560184106659134","authorId":"3560184106659134","name":"Shernice軒嬣 2000","avatar":"https://community-static.tradeup.com/news/6eb28f05fb053c58e617cac286725dc1","crmLevel":12,"crmLevelSwitch":1,"authorIdStr":"3560184106659134","idStr":"3560184106659134"},"content":"@Ah_Meng buy more GLP-1 from $Hims & Hers Health Inc.(HIMS)$ , then order more pratas from my stall enjoy without worrying about getting fat! 😄","text":"@Ah_Meng buy more GLP-1 from $Hims & Hers Health Inc.(HIMS)$ , then order more pratas from my stall enjoy without worrying about getting fat! 😄","html":"@Ah_Meng buy more GLP-1 from $Hims & Hers Health Inc.(HIMS)$ , then order more pratas from my stall enjoy without worrying about getting fat! 😄"},{"author":{"id":"3574136058061437","authorId":"3574136058061437","name":"InverseCramer","avatar":"https://static.tigerbbs.com/fc405e9f366cb34e826787dc45d36977","crmLevel":12,"crmLevelSwitch":1,"authorIdStr":"3574136058061437","idStr":"3574136058061437"},"content":"Lai Lai lai Where is your shop??","text":"Lai Lai lai Where is your shop??","html":"Lai Lai lai Where is your shop??"}],"imageCount":3,"langContent":"EN","totalScore":0},{"id":539982143857536,"gmtCreate":1772853139676,"gmtModify":1773047808882,"author":{"id":"4125545119825582","authorId":"4125545119825582","name":"HRHRHRHR","avatar":"https://community-static.tradeup.com/news/f72f7c8c7a3f167c0f03f6041d1ff44f","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4125545119825582","idStr":"4125545119825582"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a> 7 Mar - Missed this 40%+ pump. Waited for $13 but did not happened. Congrats to those who got it at $14-$15 when no one believed in the stock.. [Miser]&nbsp; [Miser]&nbsp; [Miser]&nbsp;&nbsp;","listText":"<a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a> 7 Mar - Missed this 40%+ pump. Waited for $13 but did not happened. Congrats to those who got it at $14-$15 when no one believed in the stock.. [Miser]&nbsp; [Miser]&nbsp; [Miser]&nbsp;&nbsp;","text":"$Hims & Hers Health Inc.(HIMS)$ 7 Mar - Missed this 40%+ pump. Waited for $13 but did not happened. Congrats to those who got it at $14-$15 when no one believed in the stock.. [Miser] [Miser] [Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":11,"link":"https://ttm.financial/post/539982143857536","isVote":1,"tweetType":1,"viewCount":1586,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":539946144334528,"gmtCreate":1772844472667,"gmtModify":1773047808943,"author":{"id":"3560184106659134","authorId":"3560184106659134","name":"Shernice軒嬣 2000","avatar":"https://community-static.tradeup.com/news/6eb28f05fb053c58e617cac286725dc1","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3560184106659134","idStr":"3560184106659134"},"themes":[],"title":"Novo & Hims Tie the Knot Again 💍 Muthu Boy Cheers, Prata on the Side?","htmlText":"Divorced Last Year, Married Again This Monday? Novo &amp; Hims’ Comeback” <a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp; Novo and Hims look like they’re getting married again 💍 after last year’s messy divorce. Hims pops 35% in after hours.&nbsp; The two companies are expected to announce a new partnership as early as Monday, according to a person familiar with the matter who spoke on condition of anonymity. They were previously together, but Novo abruptly called it quits after Hims refused to stop promoting and selling copycat medications. Now it seems the former couple may be giving love another chance&nbsp; and Muthu boy is very happy to see the reunion 😊. I wonder… will they order my roti prata from my prata shop? 🥞✨","listText":"Divorced Last Year, Married Again This Monday? Novo &amp; Hims’ Comeback” <a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp; Novo and Hims look like they’re getting married again 💍 after last year’s messy divorce. Hims pops 35% in after hours.&nbsp; The two companies are expected to announce a new partnership as early as Monday, according to a person familiar with the matter who spoke on condition of anonymity. They were previously together, but Novo abruptly called it quits after Hims refused to stop promoting and selling copycat medications. Now it seems the former couple may be giving love another chance&nbsp; and Muthu boy is very happy to see the reunion 😊. I wonder… will they order my roti prata from my prata shop? 🥞✨","text":"Divorced Last Year, Married Again This Monday? Novo & Hims’ Comeback” $Hims & Hers Health Inc.(HIMS)$ Novo and Hims look like they’re getting married again 💍 after last year’s messy divorce. Hims pops 35% in after hours. The two companies are expected to announce a new partnership as early as Monday, according to a person familiar with the matter who spoke on condition of anonymity. They were previously together, but Novo abruptly called it quits after Hims refused to stop promoting and selling copycat medications. Now it seems the former couple may be giving love another chance and Muthu boy is very happy to see the reunion 😊. I wonder… will they order my roti prata from my prata shop? 🥞✨","images":[{"img":"https://community-static.tradeup.com/news/80bc2650c5017e6decb9a5260e353d74","width":"1080","height":"1936"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/539946144334528","isVote":1,"tweetType":1,"viewCount":884,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0},{"id":539763565827128,"gmtCreate":1772799778751,"gmtModify":1773047809004,"author":{"id":"3560184106659134","authorId":"3560184106659134","name":"Shernice軒嬣 2000","avatar":"https://community-static.tradeup.com/news/6eb28f05fb053c58e617cac286725dc1","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3560184106659134","idStr":"3560184106659134"},"themes":[],"title":"Patent Cliff Hits: India, China & Brazil Unlock Cheap Semaglutide – Hims & Hers Poised to Dominate Globally!","htmlText":"Big news for weight loss access! Semaglutide patents are expiring soon in countries like India, China, and Brazil (starting March 2026) – meaning super-cheap generic versions are coming!&nbsp; <a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a>&nbsp; &nbsp;Here's why this could be a game-changer for Hims &amp; Hers (and patients worldwide):&nbsp; &nbsp;Lower Costs As patents expire, raw ingredient (API) prices will crash. If manufacturing drops to ~$3/month, Hims &amp; Hers can slash subscription prices big time – making effective weight loss meds affordable instead of $200–$1,000/month for branded versions. More people can finally access it! Global Expansion Hims &amp; Hers is already pushing internationally (just entered Canada!). With cheap, legal generi","listText":"Big news for weight loss access! Semaglutide patents are expiring soon in countries like India, China, and Brazil (starting March 2026) – meaning super-cheap generic versions are coming!&nbsp; <a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a>&nbsp; &nbsp;Here's why this could be a game-changer for Hims &amp; Hers (and patients worldwide):&nbsp; &nbsp;Lower Costs As patents expire, raw ingredient (API) prices will crash. If manufacturing drops to ~$3/month, Hims &amp; Hers can slash subscription prices big time – making effective weight loss meds affordable instead of $200–$1,000/month for branded versions. More people can finally access it! Global Expansion Hims &amp; Hers is already pushing internationally (just entered Canada!). With cheap, legal generi","text":"Big news for weight loss access! Semaglutide patents are expiring soon in countries like India, China, and Brazil (starting March 2026) – meaning super-cheap generic versions are coming! $Hims & Hers Health Inc.(HIMS)$ Here's why this could be a game-changer for Hims & Hers (and patients worldwide): Lower Costs As patents expire, raw ingredient (API) prices will crash. If manufacturing drops to ~$3/month, Hims & Hers can slash subscription prices big time – making effective weight loss meds affordable instead of $200–$1,000/month for branded versions. More people can finally access it! Global Expansion Hims & Hers is already pushing internationally (just entered Canada!). With cheap, legal generi","images":[{"img":"https://community-static.tradeup.com/news/1b57f84a6f06a42d97f86453c83871e5","width":"1079","height":"1248"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":3,"commentSize":0,"repostSize":1,"link":"https://ttm.financial/post/539763565827128","isVote":1,"tweetType":1,"viewCount":758,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":539322005651776,"gmtCreate":1772699799735,"gmtModify":1773047809071,"author":{"id":"9000000000000725","authorId":"9000000000000725","name":"AfraSimon","avatar":"https://static.tigerbbs.com/46d30a827da942c1b0307f51e832534e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"9000000000000725","idStr":"9000000000000725"},"themes":[],"title":"Bear Case on $HIMS: Valuation Risk, GLP-1 Threat, and Slowing Growth","htmlText":"Pure <a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$</a> delulu copium. Bearish catalysts: 1) Still trading at 32 P/E, despite the core profit driver under attack. If GLP1s go to zero, profits fall 80-120%. Overvalued. 2) Growth is not \"sandbagged\", its the opposite. $HIMS 2026 and 2030 guidances are aggressive and unachievable without M&amp;A. 3) Newly acquired international segments are stinkers and unprofitable. Everyone knows that $HIMS is the sucker to sell to. Watch for international growth to suffer because of \"macro and War in Iran\" (Excuses). 4) Peptide approval is not the catalyst HIMS hopes for. It's the opposite, regulators are talking of banning the sale of certain peptides and stricter regulations. 5) Wearables is just delusion, HIMS can't compete w","listText":"Pure <a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$</a> delulu copium. Bearish catalysts: 1) Still trading at 32 P/E, despite the core profit driver under attack. If GLP1s go to zero, profits fall 80-120%. Overvalued. 2) Growth is not \"sandbagged\", its the opposite. $HIMS 2026 and 2030 guidances are aggressive and unachievable without M&amp;A. 3) Newly acquired international segments are stinkers and unprofitable. Everyone knows that $HIMS is the sucker to sell to. Watch for international growth to suffer because of \"macro and War in Iran\" (Excuses). 4) Peptide approval is not the catalyst HIMS hopes for. It's the opposite, regulators are talking of banning the sale of certain peptides and stricter regulations. 5) Wearables is just delusion, HIMS can't compete w","text":"Pure $Hims & Hers Health Inc.(HIMS)$ delulu copium. Bearish catalysts: 1) Still trading at 32 P/E, despite the core profit driver under attack. If GLP1s go to zero, profits fall 80-120%. Overvalued. 2) Growth is not \"sandbagged\", its the opposite. $HIMS 2026 and 2030 guidances are aggressive and unachievable without M&A. 3) Newly acquired international segments are stinkers and unprofitable. Everyone knows that $HIMS is the sucker to sell to. Watch for international growth to suffer because of \"macro and War in Iran\" (Excuses). 4) Peptide approval is not the catalyst HIMS hopes for. It's the opposite, regulators are talking of banning the sale of certain peptides and stricter regulations. 5) Wearables is just delusion, HIMS can't compete w","images":[{"img":"https://community-static.tradeup.com/news/62e040c4d73c741662d709873cd4f330"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/539322005651776","isVote":1,"tweetType":1,"viewCount":715,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0},{"id":539128842056776,"gmtCreate":1772644819381,"gmtModify":1773047809129,"author":{"id":"3582885740021561","authorId":"3582885740021561","name":"andy_88","avatar":"https://community-static.tradeup.com/news/a70af8809a95756364cc82fcfde2f404","crmLevel":13,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3582885740021561","idStr":"3582885740021561"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/OPT/HIMS 20260327 15.0 PUT\">$HIMS 20260327 15.0 PUT$ </a>&nbsp;","listText":"<a href=\"https://ttm.financial/OPT/HIMS 20260327 15.0 PUT\">$HIMS 20260327 15.0 PUT$ </a>&nbsp;","text":"$HIMS 20260327 15.0 PUT$","images":[{"img":"https://community-static.tradeup.com/news/170af9e6ea179b2bde6fb93cf8c3785b","width":"882","height":"1668"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/539128842056776","isVote":1,"tweetType":1,"viewCount":259,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":539033075241256,"gmtCreate":1772629254434,"gmtModify":1773047809188,"author":{"id":"4144906086863692","authorId":"4144906086863692","name":"NAI500","avatar":"https://community-static.tradeup.com/news/01a5cfb1c65c21d31f28a3934107c034","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4144906086863692","idStr":"4144906086863692"},"themes":[],"title":"$150 Billion Weight-Loss Drug Market Temptation: Novo Nordisk Expands Production Against the Tide","htmlText":"Facing Eli Lilly’s competition and short-term sales slumps, can NVO reclaim its GLP-1 dominance in the $150B market? Are you bullish on its long-term bet, or is LLY a better pick? Share your thoughts on the weight-loss drug race below! To consolidate its position in the global weight-loss drug market, Danish pharmaceutical giant <a href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$</a> is accelerating capacity expansion. According to local media reports on Monday, the company will invest €432 million (approximately $507 million) to upgrade its factory in Athlone, Ireland, to produce its blockbuster weight-loss drug Wegovy for markets outside the United States. A company spokesperson has confirmed the scale of this investment. The upgrade will significantly enhance its production ca","listText":"Facing Eli Lilly’s competition and short-term sales slumps, can NVO reclaim its GLP-1 dominance in the $150B market? Are you bullish on its long-term bet, or is LLY a better pick? Share your thoughts on the weight-loss drug race below! To consolidate its position in the global weight-loss drug market, Danish pharmaceutical giant <a href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$</a> is accelerating capacity expansion. According to local media reports on Monday, the company will invest €432 million (approximately $507 million) to upgrade its factory in Athlone, Ireland, to produce its blockbuster weight-loss drug Wegovy for markets outside the United States. A company spokesperson has confirmed the scale of this investment. The upgrade will significantly enhance its production ca","text":"Facing Eli Lilly’s competition and short-term sales slumps, can NVO reclaim its GLP-1 dominance in the $150B market? Are you bullish on its long-term bet, or is LLY a better pick? Share your thoughts on the weight-loss drug race below! To consolidate its position in the global weight-loss drug market, Danish pharmaceutical giant $Novo-Nordisk A/S(NVO)$ is accelerating capacity expansion. According to local media reports on Monday, the company will invest €432 million (approximately $507 million) to upgrade its factory in Athlone, Ireland, to produce its blockbuster weight-loss drug Wegovy for markets outside the United States. A company spokesperson has confirmed the scale of this investment. The upgrade will significantly enhance its production ca","images":[{"img":"https://community-static.tradeup.com/news/c5b0c71e30fb5acb30c7173a11e09e18","width":"560","height":"240"},{"img":"https://community-static.tradeup.com/news/62e040c4d73c741662d709873cd4f330","width":"1035","height":"250"},{"img":"https://community-static.tradeup.com/news/53023fe848b1b37867b56e3748a0c11c","width":"3508","height":"2480"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/539033075241256","isVote":1,"tweetType":1,"viewCount":887,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"EN","totalScore":0},{"id":538610220724424,"gmtCreate":1772525948340,"gmtModify":1773047809250,"author":{"id":"4159952822702602","authorId":"4159952822702602","name":"Travis Hoium","avatar":"https://community-static.tradeup.com/news/7f6caf1342339cc5b5ecd9bf6ff43d46","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4159952822702602","idStr":"4159952822702602"},"themes":[],"title":"$HIMS Eyes Multi-Billion-Dollar Peptide Boom as 19 Key Compounds Gain Traction","htmlText":"Peptides could be a new multi-billion-dollar market for companies like Hims &amp; Hers $HIMS. What are these peptides, and what do they do? Here's what you need to know about all 19 peptides in question today, 14 of which may soon be legal to compound (according to RFK) 👇 1. BPC-157 Note: These infographics are made by Gemini and are for informational purposes only. 2. Thymosin Alpha-1 (Ta1) 3. Thymosin Beta-4 Fragment (TB-500) 4. AOD-9604 5. CJC-1295 6. Ipamorelin Acetate 7. Selank Acetate (TP-7) 8. Semax 9. GHK-Cu (Copper Peptide) 10. GHRP-2 11. GHRP-6 12. Epitalon 13. KPV 14. Kisspeptin-10 15. Melanotan II 16. MOTS-c 17. PEG-MGF (Pegylated Mechano Growth Factor) 18. Emideltide (DSIP - Delta Sleep-Inducing Peptide) 19. Cathelicidin LL-37 For SG users only, Welcome to open a CBA today and","listText":"Peptides could be a new multi-billion-dollar market for companies like Hims &amp; Hers $HIMS. What are these peptides, and what do they do? Here's what you need to know about all 19 peptides in question today, 14 of which may soon be legal to compound (according to RFK) 👇 1. BPC-157 Note: These infographics are made by Gemini and are for informational purposes only. 2. Thymosin Alpha-1 (Ta1) 3. Thymosin Beta-4 Fragment (TB-500) 4. AOD-9604 5. CJC-1295 6. Ipamorelin Acetate 7. Selank Acetate (TP-7) 8. Semax 9. GHK-Cu (Copper Peptide) 10. GHRP-2 11. GHRP-6 12. Epitalon 13. KPV 14. Kisspeptin-10 15. Melanotan II 16. MOTS-c 17. PEG-MGF (Pegylated Mechano Growth Factor) 18. Emideltide (DSIP - Delta Sleep-Inducing Peptide) 19. Cathelicidin LL-37 For SG users only, Welcome to open a CBA today and","text":"Peptides could be a new multi-billion-dollar market for companies like Hims & Hers $HIMS. What are these peptides, and what do they do? Here's what you need to know about all 19 peptides in question today, 14 of which may soon be legal to compound (according to RFK) 👇 1. BPC-157 Note: These infographics are made by Gemini and are for informational purposes only. 2. Thymosin Alpha-1 (Ta1) 3. Thymosin Beta-4 Fragment (TB-500) 4. AOD-9604 5. CJC-1295 6. Ipamorelin Acetate 7. Selank Acetate (TP-7) 8. Semax 9. GHK-Cu (Copper Peptide) 10. GHRP-2 11. GHRP-6 12. Epitalon 13. KPV 14. Kisspeptin-10 15. Melanotan II 16. MOTS-c 17. PEG-MGF (Pegylated Mechano Growth Factor) 18. Emideltide (DSIP - Delta Sleep-Inducing Peptide) 19. Cathelicidin LL-37 For SG users only, Welcome to open a CBA today and","images":[{"img":"https://community-static.tradeup.com/news/faa758fd902cfc0b70c8df588f4a721d","width":"680","height":"371"},{"img":"https://community-static.tradeup.com/news/8e4547cf1ca7bf5d6b50ee695bd8de17","width":"680","height":"371"},{"img":"https://community-static.tradeup.com/news/b020e4987a663ca8d500fd70d623bfe5","width":"680","height":"371"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/538610220724424","isVote":1,"tweetType":1,"viewCount":377,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":21,"langContent":"EN","totalScore":0}],"essenList":[{"id":542956483367992,"gmtCreate":1773585553850,"gmtModify":1773652602565,"author":{"id":"4147681045299222","authorId":"4147681045299222","name":"Isleigh","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4147681045299222","idStr":"4147681045299222"},"themes":[],"title":"HIMS Surges 49%: Is This the Start of a Digital Healthcare Supercycle?‌","htmlText":"<a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a><v-v data-views=\"1\"></v-v> When a stock jumps nearly 50% in premarket, investors usually assume the move is already over. But sometimes, a sudden surge is not the end of a rally. It is the start of a new narrative. That may be what we are witnessing with Hims &amp; Hers Health (HIMS). The catalyst? A reported settlement between Novo Nordisk and HIMS, clearing the path for the Wegovy weight loss drug to be sold through HIMS platform. On the surface, this looks like a simple distribution agreement. In reality, it could represent something much bigger: the merging of Big Pharma with digital health infrastructure. Why the Market Reacted So Violently The 49% surge was not just excitement. It was the removal of a","listText":"<a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a><v-v data-views=\"1\"></v-v> When a stock jumps nearly 50% in premarket, investors usually assume the move is already over. But sometimes, a sudden surge is not the end of a rally. It is the start of a new narrative. That may be what we are witnessing with Hims &amp; Hers Health (HIMS). The catalyst? A reported settlement between Novo Nordisk and HIMS, clearing the path for the Wegovy weight loss drug to be sold through HIMS platform. On the surface, this looks like a simple distribution agreement. In reality, it could represent something much bigger: the merging of Big Pharma with digital health infrastructure. Why the Market Reacted So Violently The 49% surge was not just excitement. It was the removal of a","text":"$Hims & Hers Health Inc.(HIMS)$ When a stock jumps nearly 50% in premarket, investors usually assume the move is already over. But sometimes, a sudden surge is not the end of a rally. It is the start of a new narrative. That may be what we are witnessing with Hims & Hers Health (HIMS). The catalyst? A reported settlement between Novo Nordisk and HIMS, clearing the path for the Wegovy weight loss drug to be sold through HIMS platform. On the surface, this looks like a simple distribution agreement. In reality, it could represent something much bigger: the merging of Big Pharma with digital health infrastructure. Why the Market Reacted So Violently The 49% surge was not just excitement. It was the removal of a","images":[{"img":"https://community-static.tradeup.com/news/9dbaaea9f1e62490d55675083e4f7a53","width":"1024","height":"1536"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":4,"commentSize":2,"repostSize":1,"link":"https://ttm.financial/post/542956483367992","isVote":1,"tweetType":1,"viewCount":710,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3527667614729340","authorId":"3527667614729340","name":"chipzzy","avatar":"https://static.tigerbbs.com/cb1b514fb84e9876b2ede5b6bd40c4cb","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3527667614729340","idStr":"3527667614729340"},"content":"Impressive move! If it holds above $30, massive upside potential lah.[看涨]","text":"Impressive move! If it holds above $30, massive upside potential lah.[看涨]","html":"Impressive move! If it holds above $30, massive upside potential lah.[看涨]"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":539033075241256,"gmtCreate":1772629254434,"gmtModify":1773047809188,"author":{"id":"4144906086863692","authorId":"4144906086863692","name":"NAI500","avatar":"https://community-static.tradeup.com/news/01a5cfb1c65c21d31f28a3934107c034","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4144906086863692","idStr":"4144906086863692"},"themes":[],"title":"$150 Billion Weight-Loss Drug Market Temptation: Novo Nordisk Expands Production Against the Tide","htmlText":"Facing Eli Lilly’s competition and short-term sales slumps, can NVO reclaim its GLP-1 dominance in the $150B market? Are you bullish on its long-term bet, or is LLY a better pick? Share your thoughts on the weight-loss drug race below! To consolidate its position in the global weight-loss drug market, Danish pharmaceutical giant <a href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$</a> is accelerating capacity expansion. According to local media reports on Monday, the company will invest €432 million (approximately $507 million) to upgrade its factory in Athlone, Ireland, to produce its blockbuster weight-loss drug Wegovy for markets outside the United States. A company spokesperson has confirmed the scale of this investment. The upgrade will significantly enhance its production ca","listText":"Facing Eli Lilly’s competition and short-term sales slumps, can NVO reclaim its GLP-1 dominance in the $150B market? Are you bullish on its long-term bet, or is LLY a better pick? Share your thoughts on the weight-loss drug race below! To consolidate its position in the global weight-loss drug market, Danish pharmaceutical giant <a href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$</a> is accelerating capacity expansion. According to local media reports on Monday, the company will invest €432 million (approximately $507 million) to upgrade its factory in Athlone, Ireland, to produce its blockbuster weight-loss drug Wegovy for markets outside the United States. A company spokesperson has confirmed the scale of this investment. The upgrade will significantly enhance its production ca","text":"Facing Eli Lilly’s competition and short-term sales slumps, can NVO reclaim its GLP-1 dominance in the $150B market? Are you bullish on its long-term bet, or is LLY a better pick? Share your thoughts on the weight-loss drug race below! To consolidate its position in the global weight-loss drug market, Danish pharmaceutical giant $Novo-Nordisk A/S(NVO)$ is accelerating capacity expansion. According to local media reports on Monday, the company will invest €432 million (approximately $507 million) to upgrade its factory in Athlone, Ireland, to produce its blockbuster weight-loss drug Wegovy for markets outside the United States. A company spokesperson has confirmed the scale of this investment. The upgrade will significantly enhance its production ca","images":[{"img":"https://community-static.tradeup.com/news/c5b0c71e30fb5acb30c7173a11e09e18","width":"560","height":"240"},{"img":"https://community-static.tradeup.com/news/62e040c4d73c741662d709873cd4f330","width":"1035","height":"250"},{"img":"https://community-static.tradeup.com/news/53023fe848b1b37867b56e3748a0c11c","width":"3508","height":"2480"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/539033075241256","isVote":1,"tweetType":1,"viewCount":887,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"EN","totalScore":0},{"id":538610220724424,"gmtCreate":1772525948340,"gmtModify":1773047809250,"author":{"id":"4159952822702602","authorId":"4159952822702602","name":"Travis Hoium","avatar":"https://community-static.tradeup.com/news/7f6caf1342339cc5b5ecd9bf6ff43d46","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4159952822702602","idStr":"4159952822702602"},"themes":[],"title":"$HIMS Eyes Multi-Billion-Dollar Peptide Boom as 19 Key Compounds Gain Traction","htmlText":"Peptides could be a new multi-billion-dollar market for companies like Hims &amp; Hers $HIMS. What are these peptides, and what do they do? Here's what you need to know about all 19 peptides in question today, 14 of which may soon be legal to compound (according to RFK) 👇 1. BPC-157 Note: These infographics are made by Gemini and are for informational purposes only. 2. Thymosin Alpha-1 (Ta1) 3. Thymosin Beta-4 Fragment (TB-500) 4. AOD-9604 5. CJC-1295 6. Ipamorelin Acetate 7. Selank Acetate (TP-7) 8. Semax 9. GHK-Cu (Copper Peptide) 10. GHRP-2 11. GHRP-6 12. Epitalon 13. KPV 14. Kisspeptin-10 15. Melanotan II 16. MOTS-c 17. PEG-MGF (Pegylated Mechano Growth Factor) 18. Emideltide (DSIP - Delta Sleep-Inducing Peptide) 19. Cathelicidin LL-37 For SG users only, Welcome to open a CBA today and","listText":"Peptides could be a new multi-billion-dollar market for companies like Hims &amp; Hers $HIMS. What are these peptides, and what do they do? Here's what you need to know about all 19 peptides in question today, 14 of which may soon be legal to compound (according to RFK) 👇 1. BPC-157 Note: These infographics are made by Gemini and are for informational purposes only. 2. Thymosin Alpha-1 (Ta1) 3. Thymosin Beta-4 Fragment (TB-500) 4. AOD-9604 5. CJC-1295 6. Ipamorelin Acetate 7. Selank Acetate (TP-7) 8. Semax 9. GHK-Cu (Copper Peptide) 10. GHRP-2 11. GHRP-6 12. Epitalon 13. KPV 14. Kisspeptin-10 15. Melanotan II 16. MOTS-c 17. PEG-MGF (Pegylated Mechano Growth Factor) 18. Emideltide (DSIP - Delta Sleep-Inducing Peptide) 19. Cathelicidin LL-37 For SG users only, Welcome to open a CBA today and","text":"Peptides could be a new multi-billion-dollar market for companies like Hims & Hers $HIMS. What are these peptides, and what do they do? Here's what you need to know about all 19 peptides in question today, 14 of which may soon be legal to compound (according to RFK) 👇 1. BPC-157 Note: These infographics are made by Gemini and are for informational purposes only. 2. Thymosin Alpha-1 (Ta1) 3. Thymosin Beta-4 Fragment (TB-500) 4. AOD-9604 5. CJC-1295 6. Ipamorelin Acetate 7. Selank Acetate (TP-7) 8. Semax 9. GHK-Cu (Copper Peptide) 10. GHRP-2 11. GHRP-6 12. Epitalon 13. KPV 14. Kisspeptin-10 15. Melanotan II 16. MOTS-c 17. PEG-MGF (Pegylated Mechano Growth Factor) 18. Emideltide (DSIP - Delta Sleep-Inducing Peptide) 19. Cathelicidin LL-37 For SG users only, Welcome to open a CBA today and","images":[{"img":"https://community-static.tradeup.com/news/faa758fd902cfc0b70c8df588f4a721d","width":"680","height":"371"},{"img":"https://community-static.tradeup.com/news/8e4547cf1ca7bf5d6b50ee695bd8de17","width":"680","height":"371"},{"img":"https://community-static.tradeup.com/news/b020e4987a663ca8d500fd70d623bfe5","width":"680","height":"371"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/538610220724424","isVote":1,"tweetType":1,"viewCount":377,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":21,"langContent":"EN","totalScore":0},{"id":540013639611736,"gmtCreate":1772860976843,"gmtModify":1773047808822,"author":{"id":"3560184106659134","authorId":"3560184106659134","name":"Shernice軒嬣 2000","avatar":"https://community-static.tradeup.com/news/6eb28f05fb053c58e617cac286725dc1","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3560184106659134","idStr":"3560184106659134"},"themes":[],"title":"Muthu Boy Alert: Hims & Hers Health (HIMS) Jumps 37% After Hours — 39% Short Interest Could Spark $100 Short Squeeze 🚀","htmlText":"Congrats to all the <a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;&nbsp;holders — the stock just jumped 40% after hours! 🚀 Looks like <a href=\"https://ttm.financial/J/showDialog/word_explain?id=1993157573763031040&amp;word=Novo Nordisk\">Novo Nordisk</a> (<a href=\"https://ttm.financial/J/showDialog/word_explain?id=1993157573763031040&amp;word=Novo Nordisk\">Novo Nordisk</a> (NVO)) may have dropped the lawsuit and decided to partner with HIMS, selling Novo-branded <a href=\"https://ttm.financial/J/showDialog/word_explain?id=1993149254180691968&amp;word=GLP-1\">GLP-1</a> receptor agonists. $NVO Novo Nordisk on Danish newspaper Børsen: \"We are in ongoing dialogue with companies that can help improve patient access to regulatory","listText":"Congrats to all the <a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;&nbsp;holders — the stock just jumped 40% after hours! 🚀 Looks like <a href=\"https://ttm.financial/J/showDialog/word_explain?id=1993157573763031040&amp;word=Novo Nordisk\">Novo Nordisk</a> (<a href=\"https://ttm.financial/J/showDialog/word_explain?id=1993157573763031040&amp;word=Novo Nordisk\">Novo Nordisk</a> (NVO)) may have dropped the lawsuit and decided to partner with HIMS, selling Novo-branded <a href=\"https://ttm.financial/J/showDialog/word_explain?id=1993149254180691968&amp;word=GLP-1\">GLP-1</a> receptor agonists. $NVO Novo Nordisk on Danish newspaper Børsen: \"We are in ongoing dialogue with companies that can help improve patient access to regulatory","text":"Congrats to all the $Hims & Hers Health Inc.(HIMS)$ holders — the stock just jumped 40% after hours! 🚀 Looks like Novo Nordisk (Novo Nordisk (NVO)) may have dropped the lawsuit and decided to partner with HIMS, selling Novo-branded GLP-1 receptor agonists. $NVO Novo Nordisk on Danish newspaper Børsen: \"We are in ongoing dialogue with companies that can help improve patient access to regulatory","images":[{"img":"https://community-static.tradeup.com/news/d58a2174eafc0bfad283816d4fd66678","width":"1079","height":"1761"},{"img":"https://community-static.tradeup.com/news/034f2f18706ab3991c1147b39d5040b9","width":"1290","height":"1843"},{"img":"https://community-static.tradeup.com/news/cb21bdaf4165384012735cfaef880955","width":"1080","height":"1700"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":5,"commentSize":10,"repostSize":3,"link":"https://ttm.financial/post/540013639611736","isVote":1,"tweetType":1,"viewCount":2476,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3560184106659134","authorId":"3560184106659134","name":"Shernice軒嬣 2000","avatar":"https://community-static.tradeup.com/news/6eb28f05fb053c58e617cac286725dc1","crmLevel":12,"crmLevelSwitch":1,"authorIdStr":"3560184106659134","idStr":"3560184106659134"},"content":"@Ah_Meng buy more GLP-1 from $Hims & Hers Health Inc.(HIMS)$ , then order more pratas from my stall enjoy without worrying about getting fat! 😄","text":"@Ah_Meng buy more GLP-1 from $Hims & Hers Health Inc.(HIMS)$ , then order more pratas from my stall enjoy without worrying about getting fat! 😄","html":"@Ah_Meng buy more GLP-1 from $Hims & Hers Health Inc.(HIMS)$ , then order more pratas from my stall enjoy without worrying about getting fat! 😄"},{"author":{"id":"3574136058061437","authorId":"3574136058061437","name":"InverseCramer","avatar":"https://static.tigerbbs.com/fc405e9f366cb34e826787dc45d36977","crmLevel":12,"crmLevelSwitch":1,"authorIdStr":"3574136058061437","idStr":"3574136058061437"},"content":"Lai Lai lai Where is your shop??","text":"Lai Lai lai Where is your shop??","html":"Lai Lai lai Where is your shop??"}],"imageCount":3,"langContent":"EN","totalScore":0},{"id":540831323477576,"gmtCreate":1773060505956,"gmtModify":1773134625461,"author":{"id":"4176423247955812","authorId":"4176423247955812","name":"Lanceljx","avatar":"https://community-static.tradeup.com/news/09909b81957df6057776741ed24e12fe","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4176423247955812","idStr":"4176423247955812"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a> The pre-market surge in Hims &amp; Hers Health Inc. following a reported settlement with Novo Nordisk is a significant narrative shift. For months, regulatory uncertainty around weight-loss drug distribution had weighed on sentiment. If Novo’s Wegovy is indeed sold through the Hims platform, it transforms HIMS from a telehealth subscription company into a distribution gateway for GLP-1 therapies, which is a far larger market. Can it reclaim $70? A move toward the prior high is plausible, but the 49% gap introduces short-term risks. Bullish factors Direct access to FDA-approved GLP-1 drugs boosts credibility and revenue potential. Telehealth + obesity treatment is one of the fastest-growing healthcare segme","listText":"<a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a> The pre-market surge in Hims &amp; Hers Health Inc. following a reported settlement with Novo Nordisk is a significant narrative shift. For months, regulatory uncertainty around weight-loss drug distribution had weighed on sentiment. If Novo’s Wegovy is indeed sold through the Hims platform, it transforms HIMS from a telehealth subscription company into a distribution gateway for GLP-1 therapies, which is a far larger market. Can it reclaim $70? A move toward the prior high is plausible, but the 49% gap introduces short-term risks. Bullish factors Direct access to FDA-approved GLP-1 drugs boosts credibility and revenue potential. Telehealth + obesity treatment is one of the fastest-growing healthcare segme","text":"$Hims & Hers Health Inc.(HIMS)$ The pre-market surge in Hims & Hers Health Inc. following a reported settlement with Novo Nordisk is a significant narrative shift. For months, regulatory uncertainty around weight-loss drug distribution had weighed on sentiment. If Novo’s Wegovy is indeed sold through the Hims platform, it transforms HIMS from a telehealth subscription company into a distribution gateway for GLP-1 therapies, which is a far larger market. Can it reclaim $70? A move toward the prior high is plausible, but the 49% gap introduces short-term risks. Bullish factors Direct access to FDA-approved GLP-1 drugs boosts credibility and revenue potential. Telehealth + obesity treatment is one of the fastest-growing healthcare segme","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":21,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/540831323477576","isVote":1,"tweetType":1,"viewCount":1773,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":539322005651776,"gmtCreate":1772699799735,"gmtModify":1773047809071,"author":{"id":"9000000000000725","authorId":"9000000000000725","name":"AfraSimon","avatar":"https://static.tigerbbs.com/46d30a827da942c1b0307f51e832534e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"9000000000000725","idStr":"9000000000000725"},"themes":[],"title":"Bear Case on $HIMS: Valuation Risk, GLP-1 Threat, and Slowing Growth","htmlText":"Pure <a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$</a> delulu copium. Bearish catalysts: 1) Still trading at 32 P/E, despite the core profit driver under attack. If GLP1s go to zero, profits fall 80-120%. Overvalued. 2) Growth is not \"sandbagged\", its the opposite. $HIMS 2026 and 2030 guidances are aggressive and unachievable without M&amp;A. 3) Newly acquired international segments are stinkers and unprofitable. Everyone knows that $HIMS is the sucker to sell to. Watch for international growth to suffer because of \"macro and War in Iran\" (Excuses). 4) Peptide approval is not the catalyst HIMS hopes for. It's the opposite, regulators are talking of banning the sale of certain peptides and stricter regulations. 5) Wearables is just delusion, HIMS can't compete w","listText":"Pure <a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$</a> delulu copium. Bearish catalysts: 1) Still trading at 32 P/E, despite the core profit driver under attack. If GLP1s go to zero, profits fall 80-120%. Overvalued. 2) Growth is not \"sandbagged\", its the opposite. $HIMS 2026 and 2030 guidances are aggressive and unachievable without M&amp;A. 3) Newly acquired international segments are stinkers and unprofitable. Everyone knows that $HIMS is the sucker to sell to. Watch for international growth to suffer because of \"macro and War in Iran\" (Excuses). 4) Peptide approval is not the catalyst HIMS hopes for. It's the opposite, regulators are talking of banning the sale of certain peptides and stricter regulations. 5) Wearables is just delusion, HIMS can't compete w","text":"Pure $Hims & Hers Health Inc.(HIMS)$ delulu copium. Bearish catalysts: 1) Still trading at 32 P/E, despite the core profit driver under attack. If GLP1s go to zero, profits fall 80-120%. Overvalued. 2) Growth is not \"sandbagged\", its the opposite. $HIMS 2026 and 2030 guidances are aggressive and unachievable without M&A. 3) Newly acquired international segments are stinkers and unprofitable. Everyone knows that $HIMS is the sucker to sell to. Watch for international growth to suffer because of \"macro and War in Iran\" (Excuses). 4) Peptide approval is not the catalyst HIMS hopes for. It's the opposite, regulators are talking of banning the sale of certain peptides and stricter regulations. 5) Wearables is just delusion, HIMS can't compete w","images":[{"img":"https://community-static.tradeup.com/news/62e040c4d73c741662d709873cd4f330"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/539322005651776","isVote":1,"tweetType":1,"viewCount":715,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0},{"id":539763565827128,"gmtCreate":1772799778751,"gmtModify":1773047809004,"author":{"id":"3560184106659134","authorId":"3560184106659134","name":"Shernice軒嬣 2000","avatar":"https://community-static.tradeup.com/news/6eb28f05fb053c58e617cac286725dc1","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3560184106659134","idStr":"3560184106659134"},"themes":[],"title":"Patent Cliff Hits: India, China & Brazil Unlock Cheap Semaglutide – Hims & Hers Poised to Dominate Globally!","htmlText":"Big news for weight loss access! Semaglutide patents are expiring soon in countries like India, China, and Brazil (starting March 2026) – meaning super-cheap generic versions are coming!&nbsp; <a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a>&nbsp; &nbsp;Here's why this could be a game-changer for Hims &amp; Hers (and patients worldwide):&nbsp; &nbsp;Lower Costs As patents expire, raw ingredient (API) prices will crash. If manufacturing drops to ~$3/month, Hims &amp; Hers can slash subscription prices big time – making effective weight loss meds affordable instead of $200–$1,000/month for branded versions. More people can finally access it! Global Expansion Hims &amp; Hers is already pushing internationally (just entered Canada!). With cheap, legal generi","listText":"Big news for weight loss access! Semaglutide patents are expiring soon in countries like India, China, and Brazil (starting March 2026) – meaning super-cheap generic versions are coming!&nbsp; <a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a>&nbsp; &nbsp;Here's why this could be a game-changer for Hims &amp; Hers (and patients worldwide):&nbsp; &nbsp;Lower Costs As patents expire, raw ingredient (API) prices will crash. If manufacturing drops to ~$3/month, Hims &amp; Hers can slash subscription prices big time – making effective weight loss meds affordable instead of $200–$1,000/month for branded versions. More people can finally access it! Global Expansion Hims &amp; Hers is already pushing internationally (just entered Canada!). With cheap, legal generi","text":"Big news for weight loss access! Semaglutide patents are expiring soon in countries like India, China, and Brazil (starting March 2026) – meaning super-cheap generic versions are coming! $Hims & Hers Health Inc.(HIMS)$ Here's why this could be a game-changer for Hims & Hers (and patients worldwide): Lower Costs As patents expire, raw ingredient (API) prices will crash. If manufacturing drops to ~$3/month, Hims & Hers can slash subscription prices big time – making effective weight loss meds affordable instead of $200–$1,000/month for branded versions. More people can finally access it! Global Expansion Hims & Hers is already pushing internationally (just entered Canada!). With cheap, legal generi","images":[{"img":"https://community-static.tradeup.com/news/1b57f84a6f06a42d97f86453c83871e5","width":"1079","height":"1248"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":3,"commentSize":0,"repostSize":1,"link":"https://ttm.financial/post/539763565827128","isVote":1,"tweetType":1,"viewCount":758,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":542738611512536,"gmtCreate":1773532375095,"gmtModify":1773532379054,"author":{"id":"3574483723803783","authorId":"3574483723803783","name":"Liang888","avatar":"https://static.tigerbbs.com/9119b5ac937586de632c5522c9a50377","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3574483723803783","idStr":"3574483723803783"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a> #HIMS has high potential to 2x-4x from here after being going up more than 50% for the past 5 days. Very good risk to rewards.","listText":"<a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a> #HIMS has high potential to 2x-4x from here after being going up more than 50% for the past 5 days. Very good risk to rewards.","text":"$Hims & Hers Health Inc.(HIMS)$ #HIMS has high potential to 2x-4x from here after being going up more than 50% for the past 5 days. Very good risk to rewards.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/542738611512536","isVote":1,"tweetType":1,"viewCount":235,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":539946144334528,"gmtCreate":1772844472667,"gmtModify":1773047808943,"author":{"id":"3560184106659134","authorId":"3560184106659134","name":"Shernice軒嬣 2000","avatar":"https://community-static.tradeup.com/news/6eb28f05fb053c58e617cac286725dc1","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3560184106659134","idStr":"3560184106659134"},"themes":[],"title":"Novo & Hims Tie the Knot Again 💍 Muthu Boy Cheers, Prata on the Side?","htmlText":"Divorced Last Year, Married Again This Monday? Novo &amp; Hims’ Comeback” <a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp; Novo and Hims look like they’re getting married again 💍 after last year’s messy divorce. Hims pops 35% in after hours.&nbsp; The two companies are expected to announce a new partnership as early as Monday, according to a person familiar with the matter who spoke on condition of anonymity. They were previously together, but Novo abruptly called it quits after Hims refused to stop promoting and selling copycat medications. Now it seems the former couple may be giving love another chance&nbsp; and Muthu boy is very happy to see the reunion 😊. I wonder… will they order my roti prata from my prata shop? 🥞✨","listText":"Divorced Last Year, Married Again This Monday? Novo &amp; Hims’ Comeback” <a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp; Novo and Hims look like they’re getting married again 💍 after last year’s messy divorce. Hims pops 35% in after hours.&nbsp; The two companies are expected to announce a new partnership as early as Monday, according to a person familiar with the matter who spoke on condition of anonymity. They were previously together, but Novo abruptly called it quits after Hims refused to stop promoting and selling copycat medications. Now it seems the former couple may be giving love another chance&nbsp; and Muthu boy is very happy to see the reunion 😊. I wonder… will they order my roti prata from my prata shop? 🥞✨","text":"Divorced Last Year, Married Again This Monday? Novo & Hims’ Comeback” $Hims & Hers Health Inc.(HIMS)$ Novo and Hims look like they’re getting married again 💍 after last year’s messy divorce. Hims pops 35% in after hours. The two companies are expected to announce a new partnership as early as Monday, according to a person familiar with the matter who spoke on condition of anonymity. They were previously together, but Novo abruptly called it quits after Hims refused to stop promoting and selling copycat medications. Now it seems the former couple may be giving love another chance and Muthu boy is very happy to see the reunion 😊. I wonder… will they order my roti prata from my prata shop? 🥞✨","images":[{"img":"https://community-static.tradeup.com/news/80bc2650c5017e6decb9a5260e353d74","width":"1080","height":"1936"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/539946144334528","isVote":1,"tweetType":1,"viewCount":884,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0},{"id":542825922762160,"gmtCreate":1773553575007,"gmtModify":1773553578965,"author":{"id":"3571373255567067","authorId":"3571373255567067","name":"MdNasir","avatar":"https://static.tigerbbs.com/7f710cb4dfa7ce6c2ad0e54d32ba876c","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3571373255567067","idStr":"3571373255567067"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a> looking good","listText":"<a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a> looking good","text":"$Hims & Hers Health Inc.(HIMS)$ looking good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/542825922762160","isVote":1,"tweetType":1,"viewCount":137,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":541490709661008,"gmtCreate":1773227590397,"gmtModify":1773234275979,"author":{"id":"4201036395308442","authorId":"4201036395308442","name":"Pank","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4201036395308442","idStr":"4201036395308442"},"themes":[],"title":"","htmlText":"#Hims doubling due to drug approval&nbsp;","listText":"#Hims doubling due to drug approval&nbsp;","text":"#Hims doubling due to drug approval","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/541490709661008","isVote":1,"tweetType":1,"viewCount":247,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":541056315569384,"gmtCreate":1773112944900,"gmtModify":1773116418644,"author":{"id":"4228822863180962","authorId":"4228822863180962","name":"Sigmaslayer","avatar":"https://community-static.tradeup.com/news/ab2daff12c162bd81a5c90ba3a86b172","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4228822863180962","idStr":"4228822863180962"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a> indeed&nbsp;","listText":"<a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a> indeed&nbsp;","text":"$Hims & Hers Health Inc.(HIMS)$ indeed","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/541056315569384","isVote":1,"tweetType":1,"viewCount":358,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":539982143857536,"gmtCreate":1772853139676,"gmtModify":1773047808882,"author":{"id":"4125545119825582","authorId":"4125545119825582","name":"HRHRHRHR","avatar":"https://community-static.tradeup.com/news/f72f7c8c7a3f167c0f03f6041d1ff44f","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4125545119825582","idStr":"4125545119825582"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a> 7 Mar - Missed this 40%+ pump. Waited for $13 but did not happened. Congrats to those who got it at $14-$15 when no one believed in the stock.. [Miser]&nbsp; [Miser]&nbsp; [Miser]&nbsp;&nbsp;","listText":"<a href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$&nbsp;</a> 7 Mar - Missed this 40%+ pump. Waited for $13 but did not happened. Congrats to those who got it at $14-$15 when no one believed in the stock.. [Miser]&nbsp; [Miser]&nbsp; [Miser]&nbsp;&nbsp;","text":"$Hims & Hers Health Inc.(HIMS)$ 7 Mar - Missed this 40%+ pump. Waited for $13 but did not happened. Congrats to those who got it at $14-$15 when no one believed in the stock.. [Miser] [Miser] [Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":11,"link":"https://ttm.financial/post/539982143857536","isVote":1,"tweetType":1,"viewCount":1586,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":539128842056776,"gmtCreate":1772644819381,"gmtModify":1773047809129,"author":{"id":"3582885740021561","authorId":"3582885740021561","name":"andy_88","avatar":"https://community-static.tradeup.com/news/a70af8809a95756364cc82fcfde2f404","crmLevel":13,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3582885740021561","idStr":"3582885740021561"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/OPT/HIMS 20260327 15.0 PUT\">$HIMS 20260327 15.0 PUT$ </a>&nbsp;","listText":"<a href=\"https://ttm.financial/OPT/HIMS 20260327 15.0 PUT\">$HIMS 20260327 15.0 PUT$ </a>&nbsp;","text":"$HIMS 20260327 15.0 PUT$","images":[{"img":"https://community-static.tradeup.com/news/170af9e6ea179b2bde6fb93cf8c3785b","width":"882","height":"1668"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/539128842056776","isVote":1,"tweetType":1,"viewCount":259,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}]}